Emergency intensive care unit pharmacist’s intervention may reduce time to four-factor prothrombin complex concentrate administration: a retrospective study

Shoichi Imanaka¹*, Tatsuro Kuwabara¹, Hiroto Ikeda², Yasufumi Miyake², Hiromi Enomoto¹, Tetsuya Sakamoto² and Nobuhiro Yasuno¹,³

Abstract

Background: Four-factor prothrombin complex concentrate (4F-PCC) must be administered as soon as possible, and in our emergency intensive care unit (EICU), pharmacists are available on weekdays for consultation on expediting 4F-PCC administration. Although recent reports have described a reduction in time to 4F-PCC administration, few studies have addressed if this is because of EICU pharmacist’s intervention, and there are no such studies in Japan. Therefore, we aimed to examine whether EICU pharmacist’s intervention reduced time to 4F-PCC administration.

Methods: This single-center retrospective cohort study was conducted from December 2017 to May 2019. We enrolled patients who received 4F-PCC due to major bleeding or requirement of urgent surgical/invasive procedures (n = 10). Patients were divided into two groups, namely, the intervention group (n = 5), in which EICU pharmacists consulted on weekdays, and the nonintervention group (n = 5), in which an intervention was not possible because of the absence of the EICU pharmacist.

Results: The median time from patient presentation to the EICU to 4F-PCC administration (103 min vs. 111 min, p = 0.4) was similar between the two groups; however, the median time from 4F-PCC prescription ordering to administration was significantly shorter in the intervention group than in the nonintervention group (21 min vs. 60 min, p = 0.02).

Conclusions: EICU pharmacist’s intervention improves the process from 4F-PCC prescription to administration and can reduce time to 4F-PCC administration.

Keywords: Prothrombin complex concentrate, Pharmacist, Time reduction, Warfarin, Anticoagulation reversal

Background

In Japan, the four-factor prothrombin complex concentrate (4F-PCC; Kcentra®) became available in September 2017 to patients receiving warfarin therapy owing to major bleeding or requirement of urgent surgical/invasive procedures [1]. 4F-PCC must be administered as soon as possible because an early reduction in the prothrombin time-international normalized ratio (PT-INR) has been reported to reduce mortality due to major bleeding [2]. In recent years, there have been reports on the reduction of time to 4F-PCC administration [3–7]. However, in the emergency intensive care unit (EICU), during the time period between patient presentation to 4F-PCC administration, it is necessary to confirm medication histories, design the complicated prescription,
and combine intravenous vitamin K but the optimal procedure for this remains unknown.

In the United States, there are position paper and American Society of Health-System Pharmacists (ASHP) guidelines, which standardize the role of emergency department (ED) pharmacists [8, 9]. Although Japan has a Certified Pharmacist for Emergency Medicine system, the roles of ED pharmacists have not been standardized compared to those overseas. Furthermore, in the emergency system in Japan, hospitals are classified into primary, secondary and tertiary, and patients are categorized into levels according to their severity acuity, then transferred to the hospital. Therefore, ED pharmacists work according to the roles of each hospital. Because Teikyo University School of Medicine Hospital is a tertiary emergency hospital, the likelihood of patients with severe conditions being brought in is extremely high. We therefore think it is one of the roles of EICU pharmacists to administer emergency medications more appropriately and quickly. Few studies determined the effects of ED pharmacist’s intervention, and there are no such studies in Japan.

At our EICU, pharmacists are available on weekdays and offer strategies to expedite 4F-PCC administration. Therefore, we evaluated whether EICU pharmacist’s intervention reduced time to 4F-PCC administration.

Methods

Methods

This single-center retrospective cohort study was conducted from December 2017 to May 2019 because our hospital stored 10 vials of 500 units in the pharmacy department and initiated its use in December 2017. Patients who received 4F-PCC owing to major bleeding or requirement of urgent surgical/invasive procedures were enrolled. Further, patient information was extracted using electronic medical records. Exclusion criteria were 4F-PCC administration outside EICU (e.g., neurosurgical ward), administration of oral anticoagulation therapy other than warfarin, and patients not administered 4F-PCC at the time of presentation to the EICU. Patients were divided into the intervention group, in which EICU pharmacists consulted during the weekday, and the non-intervention group, in which intervention was not possible because of the absence of the EICU pharmacist.

EICU pharmacist’s intervention

Pharmacists were available for consultation on weekdays at the EICU from Monday through Friday, excluding national holidays, from 8:00 am to 5:30 pm. The details of the EICU pharmacist’s intervention are as follows (Fig. 1): (1) obtaining warfarin medication history from the patient and the medication record book at the time of patient presentation to the EICU, (2) recommending 4F-PCC therapy to the emergency physician when initial PT-INR > 2, (3) suggesting 4F-PCC dose based on the patient PT-INR and body weight, (4) advocating coadministration of intravenous vitamin K, (5) dispensing and transporting 4F-PCC from the pharmacy department to the EICU, (6) preparing 4F-PCC in the EICU, and (7) informing nurses about the infusion method to be used.

![Fig. 1 EICU pharmacist’s intervention. 4F-PCC, four factor prothrombin complex concentrate; EICU, emergency intensive care unit; PT-INR, prothrombin time-international normalized ratio](image-url)
Data collection
We obtained data on patient background (age, gender, and body weight), type of injury, reason for administration, time from patient presentation to the EICU to 4F-PCC consent form acquisition, 4F-PCC dose, 4F-PCC infusion time, coadministration of intravenous vitamin K, diagnosis of disseminated intravascular coagulation (DIC), initial PT-INR, post-4F-PCC PT-INR, and time taken for 4F-PCC administration.

Statistical analyses
The following parameters were compared between the intervention and nonintervention groups: (1) time from 4F-PCC prescription ordering to administration and (2) time from patient presentation to the EICU to 4F-PCC administration. All analyses were performed using JMP® pro 13 (SAS Institute Inc., Cary, NC, USA). Mann–Whitney U test was used to analyze continuous data, and Fisher’s exact test was used to analyze categorical data. A p value of < 0.05 was considered statistically significant.

Results
Thirteen patients received 4F-PCC during the study period. Among them, three patients were excluded because 4F-PCC had been administered in the neurosurgical ward (n = 1), the patient was on oral anticoagulation other than warfarin (n = 1) and no 4F-PCC administration at the time of EICU presentation (n = 1). Therefore, we analyzed data from 10 patients, and Table 1 lists the survey contents. In nine of the 10 patients, the 4F-PCC dose was within ±10% of the manufacturer’s prescribed individualized dosing regimen, and one patient was underdosed (A). Intravenous vitamin K was coadministered in nine of the 10 patients, except in one patient (J). Although case G did not show an accurate value exceeding 3.84 in the clinical laboratory, all patients had PT-INR > 2 before 4F-PCC administration, and PT-INR decreased after 4F-PCC administration. Although DIC is contraindicated when 4F-PCC is administered, DIC was not observed at the time of presentation to the EICU in all patients. There were no differences in baseline characteristics between the two groups.

The median time from prescription ordering to administration was significantly reduced in the intervention group (21 min vs. 60 min, p = 0.02) compared with the nonintervention group (Fig. 2); however, median time from patient presentation to the EICU to 4F-PCC administration was similar between the two groups (103 min vs. 111 min, p = 0.4) (Fig. 3).

Discussion
The effectiveness of 4F-PCC has been reported by studies in Japan and overseas [10–12], and reportedly, 4F-PCC administration shortens the time to PT-INR correction, especially when compared with conventional fresh frozen plasma [13]. Therefore, in our facility, we believe that it is important to administer 4F-PCC as soon as possible. Furthermore, we determined whether EICU pharmacist’s intervention could contribute to achieving both early and proper 4F-PCC administration by reducing the time to 4F-PCC administration based on ASHP guidelines [9].

All patients who were administered 4F-PCC had an initial PT-INR > 2, and the dosage provided was within ±10% of the recommended dosage in both groups, except in one patient. Intravenous vitamin K was administered to all patients in the intervention group but not to one of 5 patients in the nonintervention group. The infusion rate was 3 IU/kg/min or less according to the package insert. In addition, the infusion rate was maintained in all patients in the intervention group but not in one patient in the nonintervention group who received rapid intravenous infusion. Because 4F-PCC is very expensive, its proper use by pharmacists is necessary [14]. EICU pharmacists are involved in patient presentation to the EICU to 4F-PCC administration. Therefore, the following measures are being taken: (1) obtaining warfarin medication history and recommending 4F-PCC therapy to the emergency physician and (2) suggesting 4F-PCC dose and infusion rate and advocating coadministration of intravenous vitamin K. Naturally, the pharmacist in the pharmacy department can confirm the dosage in the electronic medical records. However, the time required for emergency physician to write information on the electronic records or time required for introducing a question to the prescribing emergency physician by telephone when there is a deficiency in prescription by the emergency physician becomes more necessary. Particularly, EICU pharmacists familiar with the 4F-PCC use can more reliably advocate the coadministration of intravenous vitamin K. Our results suggest that the EICU pharmacist’s intervention can contribute to the proper administration of 4F-PCC.

Regarding the time to 4F-PCC administration, the time from prescription ordering to administration was shorter by 39 min in the intervention group than in the nonintervention group. This reduction in time in the intervention group was probably because of the following reasons: (1) in the intervention group, 4F-PCC was stored in the pharmacy department rather than in the EICU, and cooperation between pharmacists in the EICU and the pharmacy department facilitated quick dispensation and transportation of 4F-PCC from the pharmacy to the EICU and (2) the EICU pharmacist confirmed the dose and promptly prepared 4F-PCC. It was suggested that the active involvement of the EICU pharmacist from the patient’s condition confirmation to the 4F-PCC administration in the immediate vicinity of
Table 1 4F-PCC Administration Characteristics

| No. | Age   | Median (IQR) | Body Weight (kg) | 4F-PCC dose (IU/kg) | Infusion time (min) | IV Vitamin K | Initial PT-INR | Post-4F-PCC PT-INR | Consent form acquisition time (min) | Time from patient presentation to prescription ordering (min) | Time from prescription ordering to administration (min) | Type of injury | Reason for administration |
|-----|-------|--------------|------------------|---------------------|---------------------|---------------|----------------|-------------------|-------------------------------------|-----------------------------------------------|-----------------------------------------------|---------------|--------------------------|
| A   | 77(F) | 74 (70–79)   | 55.5             | 55.5 (42.1–66.4)    | 18.0                | 8             | +              | 2.20              | 1.32                  | 105                            | 103 (67–121)                       | 105                          | ASDH          | Bleeding                 |
| B   | 82(F) | 38.0         | 26.0             | 26.0                | 8                   | 8             | +              | 3.69              | 1.39                  | 103                            | 87                            | 16                          | Pelvic fracture | Bleeding                 |
| C   | 74(M) | 46.2         | 54.1             | 12                  | +                   | 11.98         | 1.42           | 137               | 105                   | 39                            | Pelvic fracture                  | Cholecystitis | Urgent procedures | Bleeding |
| D   | 68(F) | 73.8         | 47.4             | 17                  | +                   | 7.94          | 1.44           | 93                | 72                    | 21                            | Sepsis                        | Urgent procedures | Bleeding                 |
| E   | 72(M) | 59.0         | 25.4             | 24                  | +                   | 3.94          | 1.37           | 41                | 17                    | 24                            | Liver damage                    | Bleeding                     |               |                          |
| F   | 89(F) | 48.0         | 480 (42.5–63.8) | 23.3                | IV                  | 3.84<         | 1.40           | 79                | 95                    | 74                            | ASDH                          | ICH                         | Bleeding                 |
| G   | 90(M) | 73.0         | 24.0             | 17                  | +                   | 2.95          | 1.15           | 45 (22–128)       | 46                    | 157                           | ICH                           | Bleeding                 |
| H   | 94(F) | 48.0         | 25.0             | 19                  | +                   | 2.07          | 1.30           | 10                | 37                    | 33                            | Traumatic pneumothorax            | Bleeding                 |
| I   | 71(F) | 42.0         | 38.8             | 16                  | +                   | 5.02          | 1.45           | 34                | 34                    | 60                            | Pelvic fracture                  | Bleeding                 |

4F-PCC: four factor prothrombin complex concentrate; A-E: Intervention group; F-J: Nonintervention group; PT-INR: prothrombin time-international normalized ratio; IQR: interquartile range; ASDH: acute subdural hemorrhage; ICH: intracranial hemorrhage; IV: intravenous
the emergency physician in real-time greatly contributed. Similar to our study, studies in other countries have reported a decrease in time from prescription ordering to 4F-PCC administration owing to better pharmacy management and ED pharmacist’s intervention [4, 5].

In contrast, there was no difference between the two groups in the time taken from patient presentation to the EICU to 4F-PCC administration, possibly because of the following factors: (1) consent form acquisition time (103 min vs. 45 min, \( p = 0.29 \)) was not different between the
groups, although it took longer in the intervention group than in the nonintervention group and (2) because all patients received 4F-PCC after warfarin administration, it took a long time to determine PT-INR and body weight required for designing the prescription. However, Dalila et al. reported that a clinical pharmacist’s intervention decreased the time taken from patient presentation to the EICU to 4F-PCC administration by 140 min and shorter ICU length of stay [6]. Further, Jessica et al. determined that PT-INR ≥ 2 and intracranial hemorrhage was confirmed on imaging but not on patient presentation [7]. These studies suggest that various factors, such as time required for prescription ordering (especially in terms of determining PT-INR and body weight) and a patient’s family relationship, must be considered.

As a limitation of this study, the number of medical professionals is often lower at night and on holidays than on weekdays. We considered the same in our hospital, especially at night. However, because EICU has a higher number of medical staff members than other wards according to facility standards, the impact is considered small. Thus, it is necessary to increase the deployment time of EICU pharmacists in our hospital because pharmacists are permanently stationed in EICUs for 24 h in some institutions in Japan [15]. Many hospitals overseas have protocols for emergency warfarin reversal [16], and similarly, some hospitals in Japan have in-house guidelines for proper use [17]. Therefore, we need to develop a protocol for appropriate 4F-PCC administration, conduct workshops, and reduce time to 4F-PCC administration in the absence of EICU pharmacists.

We could not find any clinical outcome in this study. Because the time from prescription ordering to 4F-PCC administration was reduced by the intervention of the EICU pharmacist, further investigation of the factors contributing to the shortening of the time from patient presentation to the EICU to 4F-PCC administration may lead to shortening the ICU length of stay in Japan. Therefore, we hope to achieve the above by increasing the number of cases, clarifying the problems, and investigating the factors for the reduction of 4F-PCC administration time.

**Conclusion**

EICU pharmacist’s intervention can improve the process from 4F-PCC prescription to its administration and may reduce time to 4F-PCC administration.

The main content of this paper was presented at the 47th Annual Meeting of the Japanese Association for Acute Medicine (Tokyo, 2019).

**Acknowledgements**

Not applicable.

**Authors’ contributions**

SI and TK designed the study and collected data. SI, TK, and HE drafted the manuscript. HI, YM, TS, and NY provided advice on the manuscript. All authors read and approved the final manuscript.

**Funding**

Not applicable.

**Availability of data and materials**

All data generated or analyzed during this study are included in this published article.

**Ethics approval and consent to participate**

This study protocol was approved by the Teikyo University Ethics Committee (Approval No. 19–050).

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1Pharmaceutical Department, Teikyo University School of Medicine Hospital, 2-11-1 Kaga, Itabashi-Ku, Tokyo 173-8605, Japan. 2Department of Emergency Medicine, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi-Ku, Tokyo 173-8605, Japan. 3Laboratory of Hospital Pharmacy Sciences, Faculty of Pharma Science, Teikyo University, 2-11-1 Kaga, Itabashi-Ku, Tokyo 173-8605, Japan.

**Received:** 18 December 2019 **Accepted:** 3 March 2020

**Published online:** 03 April 2020

**References**

1. The package insert of Kcentra® in Japan. CSL Behring Co Ltd. https://csl-info.com/static/assets/products/9::kcentra.pdf. Accessed 6 Dec 2019.
2. Menzin J, Hoesche J, Friedman M, Nichols C, Bergman C, Gowther M, et al. Failure to correct international normalized ratio and mortality among patients with warfarin-related major bleeding: an analysis of electronic health records. J Thromb Haemost. 2012;10:596–605.
3. Stratton M, Grurich P, Heim K, Mackey S, Burns J. Feasibility of a collaborative, prospective interdisciplinary review and pharmacy-based dispensing process for Prothrombin complex concentrate. Ann Pharmacother. 2018;52:454–61.
4. Alafaj SJ, Jarrell DH, Patanwala AE. Comparison of drug administration logistics between prothrombin complex concentrates and plasma in the emergency department. J Emerg Med. 2018;56:2182–6.
5. Langstraat E, Martiellini A, Spooelhof B, Shah S. Effect of pharmacy management on turnaround time of 4-factor prothrombin complex concentrate. Am J Health Syst Pharm. 2017;74:61–6.
6. Manic D, Hidalgo DC, Kuhrau S, Chaney W, Rech MA. Pharmacist presence decreases time to Prothrombin complex concentrate in emergency department patients with life-threatening bleeding and urgent procedures. J Emerg Med. 2019;57:620–8.
7. Corio JL, Sin JH, Hayes BD, Goldstein JN, Fuh L. Impact of a pharmacist-driven Prothrombin complex concentrate protocol on time to Administration in Patients with Warfarin-associated Intracranial Hemorrhage. West J Emerg Med. 2018;19:849–54.
8. Rudis ML, Brandt KM. Position paper on critical care pharmacy services. Pharmacotherapy. 2000;20:1400–6.
9. Eppert HD, Reznek AJ. American Society of Health-System Pharmacists. ASHP guidelines on emergency medicine pharmacist services. Am J Health Syst Pharm. 2011;68:881–95.
10. Kishimoto S, Fukiioka T, Kikuta A, Toyoda K, Brainsky A, Harman A, et al. Efficacy and safety of a 4-factor prothrombin complex concentrate for rapid vitamin K antagonist reversal in Japanese patients presenting with major bleeding or requiring urgent surgical or invasive procedures: a prospective, open-label, single-arm phase 3b study. Int J Hematol. 2017;106:777–86.

**Abbreviations**

4F-PCC: Four-factor prothrombin complex concentrate; ASHP: American Society of Health-System Pharmacists; DIC: Disseminated intravascular coagulation; ED: Emergency department; EICU: Emergency intensive care unit; PT-INR: Prothrombin time-international normalized ratio
11. Goldstein JN, Refaai MA, Milling TJ Jr, Lewis B, Goldberg-Alberts R, Hug BA, et al. Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomized trial. Lancet. 2015;385:2077–87.

12. Sarode R, Milling TJ Jr, Refaai MA, Mangione A, Schneider A, Dum BL, et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIb study. Circulation. 2013;128:1234–43.

13. Chai-Adisaksopha C, Hills C, Siegal DM, Movilla R, Heddle N, Iorio A, et al. Prothrombin complex concentrates versus fresh frozen plasma for warfarin reversal: A systematic review and meta-analysis. Thromb Haemost. 2016;116:879–90.

14. Faine BA, Amendola J, Homan J, Ahmed A, Mohr N. Factors associated with availability of anticoagulation reversal agents in rural and community emergency departments. Am J Health Syst Pharm. 2018;75:72–7.

15. Imai T, Chuma M, Kurauchi K, Kikuchi N, Yoshida Y, Tanjoh K. Evaluation of full-time pharmacists providing drug information in the critical care center. J Jpn Soc Hosp Pharm. 2012;48:319–22.

16. Gorlin J, Kinney S, Fung MK, Tinmouth A, BEST collaborative. Prothrombin complex concentrate for emergent reversal of warfarin: an international survey of hospital protocols. Vox Sang. 2017;112:595–7.

17. Gomi T, Watanabe H, Yoda N, Saito M, Okada K. Creating of the in-hospital guidelines on prothrombin complex concentrate to use for intracranial hemorrhage. JJSEM. 2017;20:545–50.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 1000 website views per year

At BMC, research is always in progress.
Learn more biomedcentral.com/submissions